Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug

Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug

Source: 
Xconomy
snippet: 

Just weeks ago, the FDA approved the first ever medicine made from a derivative of marijuana, a drug from GW Pharmaceuticals for a rare form of epilepsy. Yet competition already looms from San Diego’s Zogenix, thanks to new data the Emeryville, CA, company reports this morning.